EX-10.1 2 d283533dex101.htm MERGER AGREEMENT AGREEMENT AND PLAN OF MERGER BY AND AMONG ONCOGENERIX, INC., THE STOCKHOLDERS’ REPRESENTATIVE, THE PRINCIPAL STOCKHOLDERS, DARA BIOSCIENCES, INC. AND ONCOGENERIX ACQUISITION CORPORATION JANUARY 17, 2012...Agreement and Plan of Merger • May 5th, 2020 • Delaware
Contract Type FiledMay 5th, 2020 JurisdictionThis AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made as of January 17, 2012, by and among Oncogenerix, Inc., a Nevada corporation (the “Company”); the stockholders of the Company listed on the signatures pages hereto (the “Principal Stockholders”); Christopher Clement, in his capacity as the Stockholders’ Representative; DARA BioSciences, Inc., a Delaware corporation (the “Buyer”); and Oncogenerix Acquisition Corporation, a Nevada corporation (the “Merger Sub”). The Company, the Principal Stockholders, the Stockholders’ Representative, the Buyer and the Merger Sub are each referred to herein as a “Party” and collectively as the “Parties.”
AGREEMENT AND PLAN OF MERGER BY AND AMONG ONCOGENERIX, INC., THE STOCKHOLDERS’ REPRESENTATIVE, THE PRINCIPAL STOCKHOLDERS, DARA BIOSCIENCES, INC. AND ONCOGENERIX ACQUISITION CORPORATION JANUARY 17, 2012Agreement and Plan of Merger • January 17th, 2012 • DARA BioSciences, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJanuary 17th, 2012 Company Industry JurisdictionThis AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made as of January 17, 2012, by and among Oncogenerix, Inc., a Nevada corporation (the “Company”); the stockholders of the Company listed on the signatures pages hereto (the “Principal Stockholders”); Christopher Clement, in his capacity as the Stockholders’ Representative; DARA BioSciences, Inc., a Delaware corporation (the “Buyer”); and Oncogenerix Acquisition Corporation, a Nevada corporation (the “Merger Sub”). The Company, the Principal Stockholders, the Stockholders’ Representative, the Buyer and the Merger Sub are each referred to herein as a “Party” and collectively as the “Parties.”